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Background: Primary and secondary brain cancers are highly treatment resistant, and their marked angiogenesis
attracts interest as a potential therapeutic target. Recent observations reveal that the microvascular endothelium of
primary high-grade gliomas expresses prostate specific membrane antigen (PSMA). Breast cancers express PSMA
and they frequently form secondary brain tumors. Hence we report here our pilot study addressing the feasibility of
PSMA targeting in brain and metastatic breast tumors, by examining PSMA levels in all glioma grades (19 patients)
and in breast cancer brain metastases (5 patients).
Methods: Tumor specimens were acquired from archival material and normal brain tissues from autopsies. Tissue
were stained and probed for PSMA, and the expression levels imaged and quantified using automated hardware
and software. PSMA staining intensities of glioma subtypes, breast tumors, and breast tumor brain metastases were
compared statistically versus normals.
Results: Normal brain microvessels (4 autopsies) did not stain for PSMA, while a small proportion (<5%) of healthy
neurons stained, and were surrounded by an intact blood brain barrier. Tumor microvessels of the highly
angiogenic grade IV gliomas showed intense PSMA staining which varied between patients and was significantly
higher (p < 0.05) than normal brain. Grade I gliomas showed moderate vessel staining, while grade II and III gliomas
had no vessel staining, but a few (<2%) of the tumor cells stained. Both primary breast cancer tissues and the
associated brain metastases exhibited vascular PSMA staining, although the intensity of staining was generally less
for the metastatic lesions.
Conclusions: Our results align with and extend previous data showing PSMA expression in blood vessels of
gliomas and breast cancer brain metastases. These results provide a rationale for more comprehensive studies to
explore PSMA targeted agents for treating secondary brain tumors with PSMA expressing vasculature. Moreover,
given that PSMA participates in angiogenesis, cell signaling, tumor survival, and invasion, characterizing its
expression may help guide later investigations of the poorly understood process of low grade glioma progression
to glioblastoma.
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Primary and secondary brain cancers are difficult to treat
and are a major cause of cancer-related death [1-3].
Gliomas are the most common primary brain tumors,
with grades I, II, and III usually progressing to a poor
outcome over 2 to 10 years, while the aggressive grade
IV (glioblastoma; GBM) advances very rapidly within
2–3 years, causing approximately 13,000 deaths per
year [1]. Secondary brain cancers occur in an estimated
200,000 persons annually in the U.S., and account for
at least 20% of all cancer deaths yearly [4,5]. A major
source of brain metastases is adenocarcinoma of the
breast [4,5]. Approximately 200,000 women develop
breast cancer annually, and 2–3 years after diagnosis
nearly 30% develop brain metastases [6,7]. There are few
treatment options for this relatively late and lethal compli-
cation, which is more frequent in younger patients [8].
A potentially effective therapeutic strategy may derive
from the finding that the transmembrane prostate specific
membrane antigen (PSMA) is robustly expressed by the
tumor vascular endothelium in a variety of solid cancers,
including GBM and primary adenocarcinoma of the breast,
but is not evident in normal vascular endothelium, and to
only very low levels in normal prostate [9-13]. Patient
autopsy evidence and preclinical models reveal that pro-
gressive gliomas and breast tumor metastases either de-
velop new blood vessels or co-opt existing vessels [14-17].
PSMA has not been detected elsewhere in the body, except
on the luminal side of the intestinal epithelium, which is
not accessible via the vasculature, and on the apical surface
of renal proximal tubular cells, although PSMA targeted
antibodies are too large to filter through the kidney glo-
merulus [18]. Hence, it may be feasible to deliver PSMA
targeted agents to the tumor and its microvasculature to
(1) selectively destroy the vessels perfusing the tumor tissue,
(2) achieve high regional doses of drugs to overcome tumor
resistance [19], and (3) spare normal tissues, which typically
lack PSMA expression [11]. The vascular endothelium of
malignant brain tumors is potentially accessible to a PSMA
targeted agent which is important since studies show
that the tumor mass may be at least partly protected
from therapeutic agents by the blood–brain barrier (BBB)
[18,20]. Normal brain parenchyma which expresses low
levels of PSMA in a heterogeneous, sparse pattern [21],
would be expected to be protected from anti-PSMA tar-
geted antibody agents by an intact BBB [22]. Treatment
with cytotoxin-conjugated antibody or nanoparticles coated
with a PSMA ligand conjugated to cytotoxins is being ac-
tively explored [23,24], and anti-PSMA based agents have
targeted and suppressed prostate tumors in preclinical
models. Such agents are presently in multiple Phase II
clinical trials for prostate tumors and other cancers (http://
clinicaltrials.gov/ct2/show/NCT01056029; http://clinical-
trials.gov/show/NCT01695044) [25,26].A potentially significant reported finding is that breast
cancer metastases, while treatment resistant, do not in-
filtrate surrounding normal brain tissue beyond appro-
ximately 1 mm, rather they tend to increase in number
and size [27]. This suggests ablation of such metastatic
foci and a 1 mm surrounding zone may hold the promise
of substantially reducing or eradicating the intracranial
tumor burden [27]. PSMA is expressed by the blood ves-
sels of primary breast tumors [9] and importantly, there is
an initial report of PSMA expression in breast cancer
brain metastases, using manual, general methods of tissue
scanning and scoring [28].
For the present study we initially sought to determine,
using human tissue samples and fully automated optical
scanning and quantification of stained tissue sections,
PSMA expression in glioma grades I through IV. We
also investigated the intensity and uniformity of PSMA
expression by breast cancer brain metastases across pa-
tients [9]. The overarching goals of this early feasibility
effort was to extend the limited volume of current data
using precise automated slide scanning and quanti-
fication technology, and to help guide subsequent large
scale studies correlating tumor subtypes with patterns of
PSMA expression. In addition, given the known impor-
tant role of PSMA in tumor angiogenesis, further de-
scribing its expression may provide a basis for research
aimed at understanding; (1) how lower grade gliomas
evolve to the highly angiogenic glioblastomas, and (2)
how PSMA may contribute to angiogenesis and vasculo-
genic mimicry in glioblastomas.
Methods
Tumor specimens, primary and secondary brain tumors
Under our UCSD IRB approved protocol, 28 Formalin-
fixed paraffin-embedded (FFPE) samples were acquired
from clinical samples. Tissues included: 4 normal brain
samples from autopsies; primary breast cancers and related
brain metastases from 4 patients; a total of 14 patient gli-
omas, including grade I (5 patients), grade II (4 patients),
grade III (5 patients) and grade IV (GBM – 5 patients). All
glioma samples were acquired before the patients initiated
therapy, while the breast tumor metastases were acquired
after treatment for the primary tumor, which may be pre-
sumed to have been standard although this could not be
confirmed for all specimens. One sample of a meningioma
was used as a negative staining control for Von Willebrand
factor (VWF).
Sectioning and processing of paraffin imbedded tumors
and histology
Each tumor was sectioned at 4um intervals. Paraffin sections
were deparaffinized by placing slides in xylene followed by
rehydration through graded ethanol (100% - 70%) and wash-
ing in phosphate buffered saline-Tween 20 (PBS-T).
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Deparaffinized and rehydrated sections were placed in
target retrieval solution that was heated in a water bath at
96 - 98°C for 30 minutes. In order to quench endogenous
peroxidase activity, the sections were incubated for 30 mi-
nutes in 0.3% H2O2 and deionized water. After washing,
the sections were incubated for 20 minutes in diluted nor-
mal blocking serum, washed with PBS-T, and the primary
mouse antibody mAb 3E6 (Dako, Carpenteria, CA) for
PSMA was incubated on the sections overnight at 4°C.
This antibody has been widely used and has been well
validated for staining PSMA in GBM tissue by Wernicke
et al. [18]. Incubation with the primary antibody was
followed by washing and incubation with a biotinylated
anti-mouse secondary antibody (RTU Vectastain®), and
then application of Vectastain® Elite ABC Kit reagent. Ne-
gative controls omitted incubation with the primary anti-
body but included all other steps. After washing in buffer,
the slides were incubated with peroxidase substrate (DAB
Peroxidase Substrate Kit). The sections were then coun-
terstained with hematoxylin. Using the same staining pro-
tocol, alternating tumor sections were stained with a
primary antibody anti VWF murine antibody (Dako,
Carpenteria, CA) to detect the microvascular pattern and
determine whether PSMA staining corresponded to the
blood vessel pattern. A negative staining control was
established using adjacent sections of a meningioma in
which one was stained with a primary antibody for VWF
and underwent the entire staining procedure except that
the primary antibody was omitted.PSMA staining quantification
The stained sections were scanned using the digital
Scanscope® CM-1 scanner and images were subsequently
processed using ImageScope® software (Aperio Technology,
Vista, CA) with color deconvolution and separation
algorithms. All slides were scanned at an absolute
magnification of 400× [resolution of 0.25 μm/pixel
(100,000 pixels/inch)]. Aperio algorithms make use of
a color deconvolution method to separate stains, so
that quantification of individual stains avoids cross
contamination [29]. Positive Pixel Count (PPC) algorithmsFigure 1 PSMA staining in tissues samples representative of normal b
probed for PSMA showing no blood vessel staining and light staining of cecalculate the area of positive staining, the average positive
intensity (API; optical density), as well as the percentage
of weak (1+), medium (2+), and strong (3+) positive stai-
ning, relative to a staining calibration curve and normal-
ized to the image mean background intensity.
Analysis
Staining intensity data were plotted using GraphPad®
(La Jolla CA) and analyzed with a one way analysis of
variance (ANOVA) and the Wilcoxon-Mann–Whitney
test to compare relative PSMA staining intensity in tumors
versus normal brain tissues.
Results
Expression of PSMA in normal brain
In Figure 1, panels A, B and the enlargement in C are
representative of the 4 normal patient autopsies and
indicate, (1) light staining for PSMA and (2) that the
PSMA is only present on a fraction (<1%) of normal
brain cells which have been previously reported [21].
PSMA expression in glioma
Figure 2A provides a visual comparison of all four glioma
(astrocytoma) grades I through IV, and shows that grade
IV glioma blood vessels stained heavily for PSMA, while
grades II (n = 4) and III (n = 5) exhibited some staining of
tumor parenchyma cells but little vessel staining. In grade
I gliomas moderate staining was primarily localized at
tumor blood vessels. The two bottom panels of Figure 2A
are staining controls. They are adjacent sections from a
GBM, one section was stained with a PSMA primary anti-
body, and the companion section was subjected to the en-
tire staining procedure including the secondary antibody
but with the primary antibody omitted (negative control).
Figure 2B shows sections from different patients and illus-
trates that Grade I gliomas (n = 5) did show some tumor
cellular staining (arrow) in addition to vessel staining (all
panels), and further exploration needs to be pursued to
determine the identity of the stained cells. Figure 2B also
shows PSMA staining results from individual represen-
tative grade IV glioma (GBM) cases, and highlights the
heavy concentration of PSMA at tumor microvessels. Inrain. A – Normal brain showing no PSMA staining. B – Normal brain
llular elements, magnified digitally in (C) and indicated by arrows.
Figure 2 PSMA staining of grades I – IV glioma tissue Sections. A - PSMA staining of gliomas grades (I – IV). Note moderate staining of blood
vessels and some cells in grade I, only light staining of tumor cells in grades II and III, and heavy blood vessel staining of GBM (grade IV). The
bottom two staining control slides show adjacent GBM sections, one stained with the primary antibody for PSMA and the other, the negative
control, which was fully stained including the secondary antibody, but with the primary antibody omitted. B – PSMA staining for astrocytoma
grade I and grade IV (GBM). Each section represents a different patient. Arrows indicate cell staining in grade I tumor tissue Section. C – PSMA
staining of grade II and III glioma. There is some staining of cells only in grade I and although there is more staining in grade III it is also restricted
only to cells, with no blood vessel staining. Size bars in all panels indicate approximately 50 μm, except in negative control sections where they
indicate 100 μm.
Figure 3 Summary of PSMA Data. Graph showing data points,
one per patient tumor, and the mean (middle bars) and standard
error (outer bars) of PSMA relative staining intensity (normalized to
image mean background intensity) for astrocytomas of grades I – IV.
Unpaired t–test both parametric and nonparametric forms, p values
are indicated.
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grade II and III cases clearly indicates that these gliomas
exhibited light staining confined largely to cellular brain
elements.
Quantification of PSMA staining for all types of gliomas
relative to a normal brain is summarized in the graph of
Figure 3. All categories including normal controls (n = 4)
contained individuals with some staining, with the greatest
staining intensity displayed by the grade IV (GBM) cases
(n = 5) which was on average approximately three times
greater than normals. The normal brain surrounding the
tumors of glioma grades did not show PSMA staining of
the blood vessels. Although the number of patient samples
in each of the glioma categories is relatively small, in each
case the scanned staining data encompasses entire tissue
slides, the staining intensity scale is continuous and finely
divided, and the difference between all grades compared
with normals is statistically significant. As mentioned pre-
viously, grade II and III gliomas were comparable to grade
I gliomas in terms of average staining intensity, but in
grades II and III the tumor cells but not blood vessels
stained, while in grade I staining occurred both in blood
vessels and tumor cells.
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revealed a correspondence between PSMA and VWF
staining on vascular endothelial cells (Figure 4: panels A
and B). Panel C of Figure 4 indicates that other cell types
in GBM stained for PSMA, but VWF was largely confined
to the tumor microvasculature only (panel D).
PSMA staining in primary and brain metastatic breast
tumors
Breast cancer tissue exhibited a high degree of PSMA
staining that was considerably above that of normal brain
(Figure 5A and B). Figure 5A shows color coded matched
breast cancer and breast brain cancer metastases (n = 4).
Both primary breast cancer and brain metastases had va-
riable staining even within the same tumor. Breast cancer
had staining approximately five-fold greater than normals
(Figure 5B). Breast cancer brain metastases (n = 5) exhi-
bited staining that was on average approximately threefold
greater than that for normal brain (n = 4; p = 0.0007) and
in three patients was less than primary breast tumors.
Discussion
The present study measured the expression of PSMA on
human primary and secondary brain cancers to exploreFigure 4 Correspondence between PSMA and VWF staining in GBM b
stained for PSMA (A) and VWF (B). Note that these sections exhibit similar pa
and (D) (VWF) exhibit dissimilar staining patterns and tumor cells are stained
staining control purposes from a meningioma. In the left section the full stain
omitted (negative control) and VFW staining is absent, while in the adjacent,
present. Bars in A - D indicate approximately 50 μm.the feasibility of PSMA targeting for tumor selective de-
livery of therapeutic agents. The data indicated that the
PSMA is expressed on the brain tumor cells and es-
pecially the tumor blood vessels in human gliomas of
grades I and IV (Figures 2A & 3). We determined that
blood vessels in breast cancer brain metastases exhibit
PSMA, although we also found that expression intensity
varied considerably between patients (Figure 5A and B).
Normal brain tissue from tumor and non-tumor bearing
patients had a small number of PSMA positive cells
while the microvasculature had no staining (Figure 1).
This agrees with a previous report describing cellular
PSMA expression according to brain anatomical region
[21]. Our results for grade IV gliomas (GBM) align with
those of Wernicke et al. [18], and we extend the avail-
able data to include grade I to III gliomas. Wernicke
et al. also reported that PSMA staining was uniform for
14 breast cancer brain metastases and at the same inten-
sity as the primary tumors [28]. We also found PSMA
on such metastases, although with considerable varia-
tion and in general the staining intensity on metastases
was somewhat below that of the matched primary
breast tumor. Using automated, complete scanning and
quantification to yield a continuous, fine scale, welood vessels. A and B - Adjacent GBM (glioma grade IV) sections
tterns of highlighted blood vessels. The two bottom panels, (C) (PSMA)
for PSMA. (E) This panel displays two adjacent tissue sections taken for
ing procedure was used except that the primary antibody for VFW was
right section the primary antibody was included and VFW staining is
Figure 5 PSMA Staining in Breast Cancer and Brain Metastases. A – PSMA staining for breast tumors and breast tumor brain metastases pairs.
Each pair of sections is from a different breast tumor case (n = 3). Size bars in all panels indicate approximately 50 μm. B – Graph of PSMA staining
intensity for primary breast tumors and for breast tumor brain metastases, showing individual patient values and group mean (bars). The color coding
indicates those primary breast tumor and brain metastases that came from the same patient (n = 4). Although there was considerable variability, each
group included individual PSMA staining data points that were higher than the largest values for normal brain staining in terms of PSMA, these data
were significant (p < 0.05), and for 3 of 4 patients staining intensity was less for breast cancer brain metastases than for the primary breast tumors.
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nicke’s findings.
Despite the fact that primary and secondary brain tu-
mors express high levels of VEGF and are densely vascu-
larized, making anti-angiogenic therapy attractive, VEGF
inhibitors have so far been of limited benefit in brain can-
cer patients but may be potentially be effectively com-
bined with PSMA targeting [17,18,30-33]. The basis for
this is that in addition to GBM induction of angiogenesis
via VEGF, (1) at least some of the brain tumor vasculature
derives from the transdifferentiation of tumor cells and
does not depend on VEGF [34-36] and (2) PSMA induces
VEGF-independent angiogenesis in pathological condi-
tions [37]. It is also relevant that the stem-like cells driving
brain cancers and tumor-derived angiogenesis reside in
close proximity to newly formed microvessels, and the
expansion of glioma stem like cells in animal models re-
quires a microvascular supply [38,39].
Our observed variability of PSMA staining between tu-
mors of the same type, and the differential staining of
grade IV gliomas relative to lower grades needs to be com-
prehensively investigated in terms of informing and per-
sonalizing treatment regimens. All the glioma samples
were acquired before the patients were treated, and one
explanation for differential staining may be related to pre-
vious reports indicating that grade IV gliomas are highly
angiogenic compared with lower grades [40], and that
PSMA is only expressed on angiogenic vessels [41,42].
This is not entirely unexpected as for prostate cancer evi-
dence suggests that PSMA expression is greatest in high-
grade, metastatic, and hormone-insensitive tumors [43].
Another possible basis for differential staining may relateto the observation that the FOLH1 (PSMA) gene gene-
rates several splice variants, including PSMA, PSME,
PSM’, PSMA-C, PSMA-D, PSMAΔ6, and PSMAΔ18
[44,45]. Grade 1 through IV gliomas which exhibit dif-
ferent behavior and gene signatures, may also have differ-
ential expression of FOLH1 splice variants [46]. Moreover,
PSMA influences integrin activation, various signaling
pathways, and impacts survival and invasion in prostate
cancer cells [42]. Since PSMA is expressed by some GBM
tumor cells, it would be of potential interest to explore
whether different splice variants play a role in the trans-
differentiation of GBM cells into vascular elements, i.e.,
vasculogenic micmicry [47]. The possibility that the ex-
pression of FOLH1 splice variants changes according
to glioma grade and influences vascular expansion and
tumor cell invasion should be investigated in follow-up
studies.
The variability in PSMA staining observed with all
glioma grades aligns with the phenotypic heterogeneity
of gliomas and suggests that; (1) the extent and varia-
bility of PSMA staining within glioma grades needs to
be further explored in larger scale studies, and (2) tumor
PSMA levels should be characterized to better identify
patients that would potentially benefit from PSMA tar-
geted therapy. The same concept may apply to breast
cancer brain metastases given the heterogeneity that we
observed [48].
The present study has expanded on previous data to in-
clude all grades of glioma (I through IV). This is import-
ant because lower grade gliomas often progress despite
treatment and are associated with transformation to more
aggressive higher grades [49]. Elaborating on PSMA data
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represents an emerging, large clinical problem. Even pa-
tients with Her-2-positive breast tumors responding well
to trastuzumab (Herceptin®) suffer from brain metastasis
[8]. It should be noted that the present initial study was
constrained by the difficulty in acquiring tissue specimens.
A follow-up project will involve other centers to acquire a
larger number of patient samples to more accurately
quantify the variability of PSMA staining, and importantly,
to correlate PSMA levels with different grade IV glioma
(GBM) subtypes, viz., Proneural, Neural, Classical and
Mesenchymal. In addition, PSMA expression will be re-
lated to breast cancer subtype.
Conclusions
This report evaluated PSMA staining in grades I to IV
gliomas and breast cancer brain metastases. Average micro-
vessel PSMA levels in grade IV gliomas and breast cancer
brain metastases were significantly greater than for normal
brain, with variability between samples taken from different
patients. These data provide a foundation for further more
comprehensive investigations of PSMA in primary and
secondary brain tumors; (1) as a target for the selective
ablation of tumor microvasculature, (2) as a means of pre-
ferentially concentrating therapeutic agents at tumor tissue,
and (3) potentially to help understand the progression of
low grade gliomas to glioblastoma. Based on this and other
data, a prospective clinical trial in glioblastoma is in process
(http://clinicaltrials.gov/ct2/show/NCT02067156).
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